TriSalus Life Sciences Inc (TLSI) Q1 2026 Earnings Call Transcript

Why It Matters

The accelerated revenue growth and expanded capital base position TriSalus to capture a larger share of the $2.3 billion U.S. embolization market, while the broadened product suite and reimbursement support accelerate adoption of its PEDD platform.

Key Takeaways

• Revenue rose 60% YoY to $13.2M Q1
• Gross margin improved to 87% driven by efficiency
• Adjusted EBITDA loss narrowed to $0.95M
• Commercial footprint virtually doubled for 2026 expansion
• CMS code C8004 doubled reimbursable TriNet usage

Pulse Analysis

TriSalus Life Sciences is leveraging its proprietary Pressure‑Enabled Drug Delivery (PEDD) technology to address a fragmented embolization market that spans liver, thyroid, uterine and genicular procedures. By offering a suite of microcatheter‑based devices that improve drug targeting and procedural efficiency, the company taps an estimated $480 million liver‑only addressable market and a broader $2.3 billion U.S. opportunity. The recent CMS HCPCS code C8004, which expands reimbursement for simulation and mapping uses of the TriNet system, effectively doubles the reimbursable volume, removing a key barrier to adoption and encouraging physicians to integrate PEDD across multiple indications.

Financially, TriSalus delivered a robust top‑line performance, with Q1 revenue surging 60% YoY and gross margins climbing to 87% thanks to streamlined manufacturing and new product introductions. The company’s adjusted EBITDA loss narrowed dramatically to under $1 million, reflecting both higher margin sales and disciplined expense management. A $46 million equity raise, oversubscribed more than two‑fold, strengthens the balance sheet and funds the aggressive commercial rollout and clinical study pipeline that underpins its 2026 guidance of $60‑$62 million.

Strategically, the firm is virtually doubling its sales organization and expanding its portfolio from two to seven core products, including the imminent TriNet Advance pending 510(k) clearance. This breadth enables a single‑source solution for interventional radiologists, simplifying procurement and driving higher procedure volumes per account. Coupled with the expanded reimbursement landscape and early positive data from the PROTECT registry, these initiatives are set to accelerate market penetration, improve physician adoption, and sustain revenue momentum well beyond 2026.